Journal Mobile Options
Table of Contents
Vol. 81, No. 5-6, 2011
Issue release date: February 2012
Section title: Clinical Study
Oncology 2011;81:403–409
(DOI:10.1159/000335000)

Enrollment in Clinical Trials Correlates with Improved Survival in Metastatic Melanoma

Seetharamu N.a · Tu T.J.b · Christos P.d · Ott P.A.a · Berman R.S.c · Shapiro R.L.c · Osman I.b · Pavlick A.C.a, b
Departments of aMedicine, bDermatology and cSurgery, New York University School of Medicine, and dDivision of Biostatistics and Epidemiology, Weill Cornell Medical College, New York, N.Y., USA

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 11/8/2011 7:54:49 PM
Accepted: 11/8/2011
Published online: 1/20/2012
Issue release date: February 2012

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 4

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL

Abstract

Background: Although the current median survival time of stage-IV melanoma patients is less than 12 months, there is a subset of patients who experience long-term survival. Due to poor response rates to standard cytotoxic agents in metastatic melanoma, patients are encouraged to participate in clinical trials, the overall impact of which has not been studied, however. The aim of our study was to identify the factors associated with long-term survival and to determine the impact of clinical trial enrollment on patient outcome. Methods: We studied stage-IV melanoma patients prospectively enrolled at New York University Medical Center from 2002–2008. Associations between clinicopathologic variables and overall post-stage-IV survival were examined. Kaplan-Meier survival analysis was used to identify univariate predictors of post-stage-IV survival and the independent effect of these variables was assessed in a multivariate Cox proportional hazards regression model. The associations between clinicopathologic variables and long-term survival status (≧2 vs. <2 years) were examined by χ2 analysis and the independent effect of these variables on the latter was assessed in a multivariate logistic regression model. Results: Site of metastasis, treatment (systemic vs. localized) and pretreatment lactate dehydrogenase (LDH) level independently correlated with post-stage-IV survival. Participation in clinical trials and normal LDH levels were associated with a long-term survival of ≧2 years. Conclusion: Our data suggest that enrollment in clinical trials independently correlates with prolonged survival after a diagnosis of stage IV melanoma.

© 2012 S. Karger AG, Basel


  

Author Contacts

Anna C. Pavlick, MD
NYU Cancer Institute
160E 34th Street
New York, NY 10016 (USA)
Tel. +1 212 731 5431, E-Mail anna.pavlick@nyumc.org

  

Article Information

Received: November 8, 2011
Accepted: November 8, 2011
Published online: January 20, 2012
Number of Print Pages : 7
Number of Figures : 2, Number of Tables : 4, Number of References : 33

  

Publication Details

Oncology (International Journal for Cancer Research and Treatment)

Vol. 81, No. 5-6, Year 2011 (Cover Date: February 2012)

Journal Editor: Markman M. (Philadelphia, Pa.)
ISSN: 0030-2414 (Print), eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Received: 11/8/2011 7:54:49 PM
Accepted: 11/8/2011
Published online: 1/20/2012
Issue release date: February 2012

Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 4

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: http://www.karger.com/OCL


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.